Safety of Vedolizumab and Ustekinumab Compared With Anti-TNF in Pregnant Women With Inflammatory Bowel Disease
Limited data are available on the consequences of prenatal exposure to vedolizumab and ustekinumab. We aimed to compare the safety of vedolizumab and ustekinumab with that of anti-tumor necrosis factor (TNF) in pregnant women with inflammatory bowel diseases (IBD). Using nationwide, comprehensive da...
Gespeichert in:
| Veröffentlicht in: | Clinical gastroenterology and hepatology 2025-01, Vol.23 (1), p.144-153.e22 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 153.e22 |
|---|---|
| container_issue | 1 |
| container_start_page | 144 |
| container_title | Clinical gastroenterology and hepatology |
| container_volume | 23 |
| creator | Meyer, Antoine Miranda, Sara Drouin, Jérôme Weill, Alain Carbonnel, Franck Dray-Spira, Rosemary |
| description | Limited data are available on the consequences of prenatal exposure to vedolizumab and ustekinumab. We aimed to compare the safety of vedolizumab and ustekinumab with that of anti-tumor necrosis factor (TNF) in pregnant women with inflammatory bowel diseases (IBD).
Using nationwide, comprehensive data of the EPI-MERES registry, we identified pregnancies in women with IBD in France, exposed to anti-TNF, vedolizumab, and ustekinumab between 2014 and 2021. We compared pregnancy outcomes and complications in the offspring according to treatment exposure during pregnancy. We applied a propensity score matching for maternal, IBD, and pregnancy characteristics.
Three hundred ninety-eight pregnancies exposed to vedolizumab were compared with 1592 pregnancies exposed to anti-TNF; 464 pregnancies exposed to ustekinumab were compared with 1856 pregnancies exposed to anti-TNF. Overall, compared with anti-TNF, neither vedolizumab nor ustekinumab was associated with increased risks of abortion, caesarean section, stillbirth, preterm birth, serious infections, malignancies, or congenital abnormality in children. Women exposed to ustekinumab had an increased risk of small for gestational age births.
Overall, the safety of vedolizumab and ustekinumab compared with anti-TNF use during pregnancy is reassuring. Further studies are needed to confirm these findings.
[Display omitted] |
| doi_str_mv | 10.1016/j.cgh.2023.12.029 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2913449752</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1542356524000107</els_id><sourcerecordid>2913449752</sourcerecordid><originalsourceid>FETCH-LOGICAL-c353t-a3d6866dbfecab2cc01b8aece1b3371cde38d26a406cb3f4e7c918413a6d86c53</originalsourceid><addsrcrecordid>eNp9kE1v1DAQhq0KRD_gB_SCfOSS1GMnTiJOZaEfUkWRaOnRcuxJ6yWxF9tLtfz6pt2FI6eZ0TzzSvMQcgysBAbyZFma-4eSMy5K4CXj3R45gLriRdNA9WrXi1rW--QwpSWbiapr3pB90ULXCQYHxH_XA-YNDQP9gTaM7s960j3V3tLblPGn8y_zIkwrHdHSO5cf6KnPrrj5ekadp98i3nvtM70LE_rt_tIPo54mnUPc0E_hEUf62SXUCd-S14MeE77b1SNye_blZnFRXF2fXy5OrwojapELLaxspbT9gEb33BgGfavRIPRCNGAsitZyqSsmTS-GChvTQVuB0NK20tTiiHzY5q5i-LXGlNXkksFx1B7DOinegahmFzWfUdiiJoaUIg5qFd2k40YBU8-a1VLNmtWzZgVczRLnm_e7-HU_of138dfrDHzcAjg_-dthVMk49Aati2iyssH9J_4JCHCOkQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2913449752</pqid></control><display><type>article</type><title>Safety of Vedolizumab and Ustekinumab Compared With Anti-TNF in Pregnant Women With Inflammatory Bowel Disease</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Meyer, Antoine ; Miranda, Sara ; Drouin, Jérôme ; Weill, Alain ; Carbonnel, Franck ; Dray-Spira, Rosemary</creator><creatorcontrib>Meyer, Antoine ; Miranda, Sara ; Drouin, Jérôme ; Weill, Alain ; Carbonnel, Franck ; Dray-Spira, Rosemary</creatorcontrib><description>Limited data are available on the consequences of prenatal exposure to vedolizumab and ustekinumab. We aimed to compare the safety of vedolizumab and ustekinumab with that of anti-tumor necrosis factor (TNF) in pregnant women with inflammatory bowel diseases (IBD).
Using nationwide, comprehensive data of the EPI-MERES registry, we identified pregnancies in women with IBD in France, exposed to anti-TNF, vedolizumab, and ustekinumab between 2014 and 2021. We compared pregnancy outcomes and complications in the offspring according to treatment exposure during pregnancy. We applied a propensity score matching for maternal, IBD, and pregnancy characteristics.
Three hundred ninety-eight pregnancies exposed to vedolizumab were compared with 1592 pregnancies exposed to anti-TNF; 464 pregnancies exposed to ustekinumab were compared with 1856 pregnancies exposed to anti-TNF. Overall, compared with anti-TNF, neither vedolizumab nor ustekinumab was associated with increased risks of abortion, caesarean section, stillbirth, preterm birth, serious infections, malignancies, or congenital abnormality in children. Women exposed to ustekinumab had an increased risk of small for gestational age births.
Overall, the safety of vedolizumab and ustekinumab compared with anti-TNF use during pregnancy is reassuring. Further studies are needed to confirm these findings.
[Display omitted]</description><identifier>ISSN: 1542-3565</identifier><identifier>ISSN: 1542-7714</identifier><identifier>EISSN: 1542-7714</identifier><identifier>DOI: 10.1016/j.cgh.2023.12.029</identifier><identifier>PMID: 38199301</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Anti-TNF ; Antibodies, Monoclonal, Humanized - adverse effects ; Antibodies, Monoclonal, Humanized - therapeutic use ; Female ; France - epidemiology ; Gastrointestinal Agents - adverse effects ; Gastrointestinal Agents - therapeutic use ; Humans ; Infant, Newborn ; Inflammatory Bowel Disease ; Inflammatory Bowel Diseases - drug therapy ; Pregnancy ; Pregnancy Complications - drug therapy ; Pregnancy Outcome ; Tumor Necrosis Factor Inhibitors - adverse effects ; Tumor Necrosis Factor Inhibitors - therapeutic use ; Tumor Necrosis Factor-alpha - antagonists & inhibitors ; Ustekinumab ; Ustekinumab - adverse effects ; Ustekinumab - therapeutic use ; Vedolizumab ; Young Adult</subject><ispartof>Clinical gastroenterology and hepatology, 2025-01, Vol.23 (1), p.144-153.e22</ispartof><rights>2025 AGA Institute</rights><rights>Copyright © 2025 AGA Institute. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c353t-a3d6866dbfecab2cc01b8aece1b3371cde38d26a406cb3f4e7c918413a6d86c53</citedby><cites>FETCH-LOGICAL-c353t-a3d6866dbfecab2cc01b8aece1b3371cde38d26a406cb3f4e7c918413a6d86c53</cites><orcidid>0000-0003-1156-9289</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1542356524000107$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38199301$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Meyer, Antoine</creatorcontrib><creatorcontrib>Miranda, Sara</creatorcontrib><creatorcontrib>Drouin, Jérôme</creatorcontrib><creatorcontrib>Weill, Alain</creatorcontrib><creatorcontrib>Carbonnel, Franck</creatorcontrib><creatorcontrib>Dray-Spira, Rosemary</creatorcontrib><title>Safety of Vedolizumab and Ustekinumab Compared With Anti-TNF in Pregnant Women With Inflammatory Bowel Disease</title><title>Clinical gastroenterology and hepatology</title><addtitle>Clin Gastroenterol Hepatol</addtitle><description>Limited data are available on the consequences of prenatal exposure to vedolizumab and ustekinumab. We aimed to compare the safety of vedolizumab and ustekinumab with that of anti-tumor necrosis factor (TNF) in pregnant women with inflammatory bowel diseases (IBD).
Using nationwide, comprehensive data of the EPI-MERES registry, we identified pregnancies in women with IBD in France, exposed to anti-TNF, vedolizumab, and ustekinumab between 2014 and 2021. We compared pregnancy outcomes and complications in the offspring according to treatment exposure during pregnancy. We applied a propensity score matching for maternal, IBD, and pregnancy characteristics.
Three hundred ninety-eight pregnancies exposed to vedolizumab were compared with 1592 pregnancies exposed to anti-TNF; 464 pregnancies exposed to ustekinumab were compared with 1856 pregnancies exposed to anti-TNF. Overall, compared with anti-TNF, neither vedolizumab nor ustekinumab was associated with increased risks of abortion, caesarean section, stillbirth, preterm birth, serious infections, malignancies, or congenital abnormality in children. Women exposed to ustekinumab had an increased risk of small for gestational age births.
Overall, the safety of vedolizumab and ustekinumab compared with anti-TNF use during pregnancy is reassuring. Further studies are needed to confirm these findings.
[Display omitted]</description><subject>Adult</subject><subject>Anti-TNF</subject><subject>Antibodies, Monoclonal, Humanized - adverse effects</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Female</subject><subject>France - epidemiology</subject><subject>Gastrointestinal Agents - adverse effects</subject><subject>Gastrointestinal Agents - therapeutic use</subject><subject>Humans</subject><subject>Infant, Newborn</subject><subject>Inflammatory Bowel Disease</subject><subject>Inflammatory Bowel Diseases - drug therapy</subject><subject>Pregnancy</subject><subject>Pregnancy Complications - drug therapy</subject><subject>Pregnancy Outcome</subject><subject>Tumor Necrosis Factor Inhibitors - adverse effects</subject><subject>Tumor Necrosis Factor Inhibitors - therapeutic use</subject><subject>Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><subject>Ustekinumab</subject><subject>Ustekinumab - adverse effects</subject><subject>Ustekinumab - therapeutic use</subject><subject>Vedolizumab</subject><subject>Young Adult</subject><issn>1542-3565</issn><issn>1542-7714</issn><issn>1542-7714</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2025</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1v1DAQhq0KRD_gB_SCfOSS1GMnTiJOZaEfUkWRaOnRcuxJ6yWxF9tLtfz6pt2FI6eZ0TzzSvMQcgysBAbyZFma-4eSMy5K4CXj3R45gLriRdNA9WrXi1rW--QwpSWbiapr3pB90ULXCQYHxH_XA-YNDQP9gTaM7s960j3V3tLblPGn8y_zIkwrHdHSO5cf6KnPrrj5ekadp98i3nvtM70LE_rt_tIPo54mnUPc0E_hEUf62SXUCd-S14MeE77b1SNye_blZnFRXF2fXy5OrwojapELLaxspbT9gEb33BgGfavRIPRCNGAsitZyqSsmTS-GChvTQVuB0NK20tTiiHzY5q5i-LXGlNXkksFx1B7DOinegahmFzWfUdiiJoaUIg5qFd2k40YBU8-a1VLNmtWzZgVczRLnm_e7-HU_of138dfrDHzcAjg_-dthVMk49Aati2iyssH9J_4JCHCOkQ</recordid><startdate>20250101</startdate><enddate>20250101</enddate><creator>Meyer, Antoine</creator><creator>Miranda, Sara</creator><creator>Drouin, Jérôme</creator><creator>Weill, Alain</creator><creator>Carbonnel, Franck</creator><creator>Dray-Spira, Rosemary</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1156-9289</orcidid></search><sort><creationdate>20250101</creationdate><title>Safety of Vedolizumab and Ustekinumab Compared With Anti-TNF in Pregnant Women With Inflammatory Bowel Disease</title><author>Meyer, Antoine ; Miranda, Sara ; Drouin, Jérôme ; Weill, Alain ; Carbonnel, Franck ; Dray-Spira, Rosemary</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c353t-a3d6866dbfecab2cc01b8aece1b3371cde38d26a406cb3f4e7c918413a6d86c53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2025</creationdate><topic>Adult</topic><topic>Anti-TNF</topic><topic>Antibodies, Monoclonal, Humanized - adverse effects</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Female</topic><topic>France - epidemiology</topic><topic>Gastrointestinal Agents - adverse effects</topic><topic>Gastrointestinal Agents - therapeutic use</topic><topic>Humans</topic><topic>Infant, Newborn</topic><topic>Inflammatory Bowel Disease</topic><topic>Inflammatory Bowel Diseases - drug therapy</topic><topic>Pregnancy</topic><topic>Pregnancy Complications - drug therapy</topic><topic>Pregnancy Outcome</topic><topic>Tumor Necrosis Factor Inhibitors - adverse effects</topic><topic>Tumor Necrosis Factor Inhibitors - therapeutic use</topic><topic>Tumor Necrosis Factor-alpha - antagonists & inhibitors</topic><topic>Ustekinumab</topic><topic>Ustekinumab - adverse effects</topic><topic>Ustekinumab - therapeutic use</topic><topic>Vedolizumab</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Meyer, Antoine</creatorcontrib><creatorcontrib>Miranda, Sara</creatorcontrib><creatorcontrib>Drouin, Jérôme</creatorcontrib><creatorcontrib>Weill, Alain</creatorcontrib><creatorcontrib>Carbonnel, Franck</creatorcontrib><creatorcontrib>Dray-Spira, Rosemary</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical gastroenterology and hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Meyer, Antoine</au><au>Miranda, Sara</au><au>Drouin, Jérôme</au><au>Weill, Alain</au><au>Carbonnel, Franck</au><au>Dray-Spira, Rosemary</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety of Vedolizumab and Ustekinumab Compared With Anti-TNF in Pregnant Women With Inflammatory Bowel Disease</atitle><jtitle>Clinical gastroenterology and hepatology</jtitle><addtitle>Clin Gastroenterol Hepatol</addtitle><date>2025-01-01</date><risdate>2025</risdate><volume>23</volume><issue>1</issue><spage>144</spage><epage>153.e22</epage><pages>144-153.e22</pages><issn>1542-3565</issn><issn>1542-7714</issn><eissn>1542-7714</eissn><abstract>Limited data are available on the consequences of prenatal exposure to vedolizumab and ustekinumab. We aimed to compare the safety of vedolizumab and ustekinumab with that of anti-tumor necrosis factor (TNF) in pregnant women with inflammatory bowel diseases (IBD).
Using nationwide, comprehensive data of the EPI-MERES registry, we identified pregnancies in women with IBD in France, exposed to anti-TNF, vedolizumab, and ustekinumab between 2014 and 2021. We compared pregnancy outcomes and complications in the offspring according to treatment exposure during pregnancy. We applied a propensity score matching for maternal, IBD, and pregnancy characteristics.
Three hundred ninety-eight pregnancies exposed to vedolizumab were compared with 1592 pregnancies exposed to anti-TNF; 464 pregnancies exposed to ustekinumab were compared with 1856 pregnancies exposed to anti-TNF. Overall, compared with anti-TNF, neither vedolizumab nor ustekinumab was associated with increased risks of abortion, caesarean section, stillbirth, preterm birth, serious infections, malignancies, or congenital abnormality in children. Women exposed to ustekinumab had an increased risk of small for gestational age births.
Overall, the safety of vedolizumab and ustekinumab compared with anti-TNF use during pregnancy is reassuring. Further studies are needed to confirm these findings.
[Display omitted]</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>38199301</pmid><doi>10.1016/j.cgh.2023.12.029</doi><orcidid>https://orcid.org/0000-0003-1156-9289</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1542-3565 |
| ispartof | Clinical gastroenterology and hepatology, 2025-01, Vol.23 (1), p.144-153.e22 |
| issn | 1542-3565 1542-7714 1542-7714 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2913449752 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Anti-TNF Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Female France - epidemiology Gastrointestinal Agents - adverse effects Gastrointestinal Agents - therapeutic use Humans Infant, Newborn Inflammatory Bowel Disease Inflammatory Bowel Diseases - drug therapy Pregnancy Pregnancy Complications - drug therapy Pregnancy Outcome Tumor Necrosis Factor Inhibitors - adverse effects Tumor Necrosis Factor Inhibitors - therapeutic use Tumor Necrosis Factor-alpha - antagonists & inhibitors Ustekinumab Ustekinumab - adverse effects Ustekinumab - therapeutic use Vedolizumab Young Adult |
| title | Safety of Vedolizumab and Ustekinumab Compared With Anti-TNF in Pregnant Women With Inflammatory Bowel Disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T22%3A47%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20of%20Vedolizumab%20and%20Ustekinumab%20Compared%20With%20Anti-TNF%20in%20Pregnant%20Women%20With%20Inflammatory%20Bowel%20Disease&rft.jtitle=Clinical%20gastroenterology%20and%20hepatology&rft.au=Meyer,%20Antoine&rft.date=2025-01-01&rft.volume=23&rft.issue=1&rft.spage=144&rft.epage=153.e22&rft.pages=144-153.e22&rft.issn=1542-3565&rft.eissn=1542-7714&rft_id=info:doi/10.1016/j.cgh.2023.12.029&rft_dat=%3Cproquest_cross%3E2913449752%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2913449752&rft_id=info:pmid/38199301&rft_els_id=S1542356524000107&rfr_iscdi=true |